Balazs Halmos · @BalazsHalmosMD“Are you into Intismeran- the new “individualized neoantigen therapy” (graciously avoiding the term “vaccine”) from Merck/Moderna? If you haven’t- you should! Maybe biggest news in onc for some time along w daraxonrasib- positive results in pivotal melanoma trial as to RFS improvement of this Space age technology which still makes my head spin- whole genome seq- neoantigen selection- personalized “INT” delivered to your patient in just a few weeks… and it works! Many studies ongoing in lung/bladder etc- eager to learn results (and continue to offer to our pts at Monte @BrendonStilesMD !) Now Back to the Future and let’s keep enrolling!”
View post ↗Follow the KOL reaction to the INTerpath-001 trial update →The phase III Panku-Lung01 trial of the investigational EGFR-HER3 bispecific ADC iza-bren (izalontamab brengitecan) met its primary endpoint, showing superior PFS versus platinum doublet chemotherapy in EGFR-mutant NSCLC after progression on an EGFR-TKI. Phase 1B data for the same agent in extensive-stage SCLC showed an ORR of 48.1% and a median OS of 12.2 months. Separately, the phase III INTerpath-002 trial is evaluating the investigational personalized mRNA vaccine V940 (mRNA-4157) with pembrolizumab in resected stage II-IIIB NSCLC.
“Beyond today's phase 3 win in resected melanoma, Moderna are running the same personalized mRNA vaccine program in: Phase 3 trials - Resected non-small cell lung cancer (with pembrolizumab)”
— @DrSamuelBHume · V940 mRNA vaccine program · View post ↗
“Phase III Panku-Lung01 study of iza-bren (EGFR-HER3 bispecific ADC) vs platinum doublet chemotherapy positive in EGFR mutant NSCLC post TKI. Iza-bren showed superior PFS with OS trend, per press release.”
— @StephenVLiu · Panku-Lung01 trial · View post ↗📌 Amplified by @KolPulseAI
“Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific ADC in Extensive-Stage Small Cell Lung Cancer @JCO_ASCO M=52 Phase 1B 🔹 ORR: 48.1%; median PFS: 4.1 mo; median OS: 12.2 mo”
— @Latinamd · Iza-bren in SCLC · View post ↗📌 Amplified by @KolPulseAI
“Thanks @IASLC for the opportunity to share our comment in #ILCN on new approach of de-escalation of TKI treatment with ctDNA in pts with NSCLC.”
— @ChristianRolfo · ctDNA-guided TKI de-escalation · View post ↗📌 Amplified by @KolPulseAI
Personalized mRNA neoantigen vaccines are showing signs of success in triple negative breast cancer. Separately, the breast oncology community is discussing the potential role for oral SERDs, such as the investigational agent giredestrant, in the early-stage setting.
“The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer”
— @EricTopol · mRNA vaccines · View post ↗
“Can oral SERDs do more in early breast cancer?”
— @breastfriendspd · Oral SERDs · View post ↗
“Opening the 2026 #DAVABreast with Dr. Dennis Slamon’s lecture on Target selection in breast cancer. HER2 checks all the boxes”
— @antgiorda · HER2 targeting · View post ↗The ESMO pancreatic cancer guideline added a level IA second-line recommendation for daraxonrasib — a guideline recommendation, not a regulatory action. Daraxonrasib is investigational and is not approved by the FDA, the EMA, or any other regulator; the FDA has granted it Breakthrough Therapy and Orphan Drug designations for previously treated metastatic PDAC with RAS G12 mutations, and cleared an expanded-access protocol in May 2026. The guideline update follows RASolute 302, in which daraxonrasib roughly doubled overall survival versus chemotherapy in previously treated metastatic pancreatic cancer (13.2 vs 6.7 months, HR 0.40). Separately, on August 17, 2026 the FDA granted a Humanitarian Device Exemption — a rare-disease device pathway requiring probable benefit rather than demonstrated effectiveness — to the OncoSil device for patients over 21 with unresectable, non-metastatic distal cholangiocarcinoma, as an adjunct to systemic chemotherapy.
“Science moved faster than access. Daraxonrasib is already in the new ESMO pancreatic cancer guideline before regulatory approval. How do we make access catch up?”
— @DrYukselUrun · Daraxonrasib Access · View post ↗📌 Amplified by @KolPulseAI
“Compared with chemotherapy, treatment with daraxonrasib more than doubled OS and PFS for patients with previously treated metastatic pancreatic cancer.”
— @JournalCancer · RASolute 302 Data · View post ↗
“Congrats to cholangiocarcinoma community, @OncoSil @curecc @UTMDAnderson @lisamariecraine for HDE approval by FDA in Distal CCa”
— @JavleMilind · OncoSil FDA Approval · View post ↗
“Tumor response to neoadjuvant treatment as a predictor of benefit for adjuvant treatment in esophago-gastric cancers: a systematic review and meta-analysis”
— @Erman_Akkus · Neoadjuvant Treatment Response · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
The Phase 3 INTerpath-001 trial of the personalized mRNA vaccine V940 (mRNA-4157) was positive in melanoma, with attention now on its expansion into GU cancers in the INTerpath-004 (adjuvant RCC) and INTerpath-005 (MIUC) trials. A separate study in JAMA Oncology found that initiating ADT plus an ARPI in prostate cancer patients is associated with a high 12-month cumulative incidence of new hypertension (83%) and metabolic syndrome (39%). Additionally, updated SITC guidelines for immunotherapy in RCC recommend against using PD-L1, TMB, or MSI to guide treatment selection, noting that sarcomatoid features favor IO.
“In a phase 2 trial earlier this year the vaccine with immunotherapy has shown ~49% lower risk of recurrence or death vs immunotherapy alone, which is the current standard of care.”
— @YannickBuccella · mRNA Vaccine V940 · View post ↗📌 Amplified by @KolPulseAI
“📊 12-mo cumulative incidence: 🔺 New HTN 83% 🔺 Dyslipidemia 52% 🔺 Metabolic syndrome 39% ⏱️ Median time to 1st abnormality: 1 mo. MetS: 2.6 mo”
— @Adam_Weiner535 · ADT + ARPI Metabolic Dysfunction · View post ↗
“Will the melanoma signal translate to GU cancers? - INTerpath-004: V940 + pembro vs pembro in adjuvant RCC - INTerpath-005: V940 + pembro vs pembro in MIUC”
— @scocmem · mRNA Vaccine V940 · View post ↗
“SITC clinical practice guideline (v3.0) on immunotherapy in RCC: updated recommendations across adjuvant and metastatic settings, special populations, response monitoring, and QoL.”
— @drenriquegrande · SITC Guidelines for RCC · View post ↗The ENDURANCE trial (E1A11, ECOG-ACRIN), published in NEJM, compared continuous versus two-year fixed-duration lenalidomide maintenance in standard-risk newly diagnosed myeloma in patients not undergoing up-front autologous stem-cell transplantation. At a median seven years of follow-up, overall survival was 69.0% with continuous therapy versus 68.6% with two years: ENDURANCE showed no survival benefit from continuing beyond two years, at the cost of added toxicity. Separately, on August 13, 2026 the FDA granted accelerated approval to iberdomide (Zenbexus, Bristol Myers Squibb), the first CELMoD protein degrader, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. The FDA granted that accelerated approval on the basis of MRD-negative complete response in EXCALIBER-RRMM; continued FDA approval may be contingent on confirmatory trials. Ongoing debate in the community centers on the optimal sequencing of BCMA-directed therapies, including CAR-T, bispecific antibodies, and ADCs.
“Modern analysis of 🇺🇸 access to CAR-T in myeloma... we still have work to do.”
— @RahulBanerjeeMD · CAR-T Access · View post ↗📌 Amplified by @KolPulseAI
“Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma - ENDURANCE [Jul 15, 2026] @myelomaMD et al. @VincentRK @NEJM”
— @mtmdphd · ENDURANCE Trial · View post ↗
“Last week's FDA approval of the first CELMoD protein degrader for relapsed/refractory multiple myeloma made that trade tangible.”
— @n8pennell · CELMoD Approval · View post ↗📌 Amplified by @KolPulseAI
“🧬CAR-T before bispecifics? In this latest episode of @OncUpdates #MaximilianMerz and I discuss how and why we choose BCMA-directed therapies in relapsed/refractory multiple myeloma-plus exceptions for elderly/high-risk patients and what we still don't know about delayed neurotoxicities.”
— @hhashmi87 · BCMA Therapy Sequencing · View post ↗📌 Amplified by @KolPulseAI
Early results for the combination of mosunetuzumab, polatuzumab, and obinutuzumab in untreated indolent non-Hodgkin lymphoma (NHL) showed high rates of complete response with undetectable ctDNA, supporting ongoing randomized trials. Separately, a preclinical study in Nature identified that deleting genes P2RY8 and GNAS in T cells improved tumor clearance in a mouse model, suggesting a potential strategy for enhancing T-cell therapies.
“Delete both: in one preclinical model, 4 of 6 mice cleared their tumors, vs 1 of 6 with GNAS deletion alone.”
— @ilyassahinMD · Preclinical T-cell therapy · View post ↗📌 Amplified by @KolPulseAI
“Mosunetuzumab, Polatuzumab and Obinutuzumab in Untreated Indolent NHL: These early results provide strong evidence for ongoing large randomized trials in this space. High rates of CR with undetectable ctDNA suggest durable benefit.”
— @DrJFriedberg · Indolent NHL combination therapy · View post ↗
“The FDA’s approval of an all-oral regimen for newly diagnosed AML will have substantial impact on individual patients, as well as the operational workflows and care models at cancer centers.”
— @ASH_hematology · AML regulatory · View post ↗